What is Benchmark’s Estimate for EBS Q1 Earnings?

Emergent Biosolutions Inc. (NYSE:EBS) – Equities researchers at Benchmark issued their Q1 2026 EPS estimates for Emergent Biosolutions in a report issued on Tuesday, April 21st. Benchmark analyst R. Wasserman anticipates that the biopharmaceutical company will post earnings per share of ($0.25) for the quarter.

Other equities research analysts also recently issued reports about the stock. Wall Street Zen lowered shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. HC Wainwright dropped their price target on Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating for the company in a research note on Monday, March 9th. Finally, Weiss Ratings downgraded Emergent Biosolutions from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, March 2nd. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $12.00.

Emergent Biosolutions Price Performance

Shares of NYSE:EBS opened at $8.08 on Thursday. The company has a market cap of $417.35 million, a P/E ratio of 9.62 and a beta of 2.35. The business has a fifty day simple moving average of $8.81 and a 200-day simple moving average of $10.34. Emergent Biosolutions has a 52 week low of $4.71 and a 52 week high of $14.06. The company has a quick ratio of 2.41, a current ratio of 5.01 and a debt-to-equity ratio of 1.09.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.54). Emergent Biosolutions had a net margin of 7.08% and a return on equity of 15.86%. The business had revenue of $148.70 million during the quarter, compared to analyst estimates of $217.50 million.

Institutional Investors Weigh In On Emergent Biosolutions

Hedge funds have recently modified their holdings of the stock. Torren Management LLC purchased a new position in Emergent Biosolutions in the 4th quarter worth approximately $37,000. CANADA LIFE ASSURANCE Co acquired a new stake in Emergent Biosolutions during the 4th quarter valued at $45,000. Legal & General Group Plc acquired a new stake in Emergent Biosolutions during the 2nd quarter valued at $31,000. Farther Finance Advisors LLC increased its stake in Emergent Biosolutions by 361.3% during the 4th quarter. Farther Finance Advisors LLC now owns 6,163 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 4,827 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in Emergent Biosolutions in the 2nd quarter worth $53,000. 78.40% of the stock is currently owned by hedge funds and other institutional investors.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.